Synthorx

About Synthorx

Synthorx is a biotechnology company specializing in the design and development of protein therapeutics, known as Synthorins, aimed at treating cancer and autoimmune disorders. The company leverages a novel DNA base pair technology to create optimized and tailored medicines, representing a significant advancement in protein design. Synthorx primarily serves patients suffering from severe diseases, focusing on improving their quality of life through innovative medical solutions. Operating in the biopharmaceutical market, Synthorx's business model involves extensive research and development, followed by clinical trials to validate the efficacy of their therapeutics. Revenue is generated through the commercialization of these therapeutics, partnerships, and collaborations with other pharmaceutical companies. The company has successfully raised significant capital through public offerings and private funding rounds, enabling continuous innovation and expansion of their therapeutic pipeline.